Safety Assessment of Polyurethanes as Used in Cosmetics

Status: Release Date: Panel Meeting Date: Final Report October 13, 2017 September 11-12, 2017

The 2017 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This report was prepared by Lillian C. Becker, Scientific Analyst/Writer.

© Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ◊ Washington, DC 20036-4702 ◊ ph 202.331.0651 ◊ fax 202.331.0088 <u>cirinfo@cir-safety.org</u>

ABSTRACT

The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) assessed the safety of 66 polyurethane ingredients as used in cosmetics. The functions of these ingredients include artificial nail builders, binders, and surface modifiers. The Panel reviewed available data related to these ingredients and determined that there would be no detectable residual isocyanate or other monomers in these ingredients. The Panel concluded that these polyurethanes are safe in the practices of use and concentration of this safety assessment.

INTRODUCTION

This is a safety assessment of polyurethane ingredients as used in cosmetics. According to the *web-based International Cosmetic Ingredient Dictionary and Handbook* (wINCI *Dictionary*), the functions of these 66 ingredients include artificial nail builders, binders, film formers, hair fixatives, plasticizers, and surface modifiers (Table 1).¹ The ingredients in this group are:

Polyurethane-1	Polyurethane-25	Polyurethane-51
Polyurethane-2	Polyurethane-26	Polyurethane-52
Polyurethane-4	Polyurethane-27	Polyurethane-53
Polyurethane-5	Polyurethane-28	Polyurethane-54
Polyurethane-6	Polyurethane-29	Polyurethane-55
Polyurethane-7	Polyurethane-32	Polyurethane-56
Polyurethane-8	Polyurethane-33	Polyurethane-57
Polyurethane-9	Polyurethane-34	Polyurethane-58
Polyurethane-10	Polyurethane-35	Polyurethane-59
Polyurethane-11	Polyurethane-36	Polyurethane-60
Polyurethane-12	Polyurethane-39	Polyurethane-61
Polyurethane-13	Polyurethane-40	Polyurethane-62
Polyurethane-14	Polyurethane-41	Polyurethane-63
Polyurethane-15	Polyurethane-42	Polyurethane-64
Polyurethane-16	Polyurethane-43	Polyurethane-65
Polyurethane-17	Polyurethane-44	Polyurethane-66
Polyurethane-18	Polyurethane-45	Polyurethane-67
Polyurethane-19	Polyurethane-46	Polyurethane-68
Polyurethane-20	Polyurethane-47	Polyurethane-69
Polyurethane-21	Polyurethane-48	Polyurethane-70
Polyurethane-23	Polyurethane-49	Polyurethane-71
Polyurethane-24	Polyurethane-50	Polyurethane-72

These ingredients are copolymers containing carbamate (i.e., urethane) linkages. Some of these polyurethane ingredients, as defined, are dispersed in water (e.g., Polyurethane-17, -35, -36, -58, -60, -61, -70, -71, and -72).¹ Many of these polyurethanes are reported to be supplied to formulators in an emulsion or solution that may consist of several chemicals, creating complicated mixtures.

Polyurethane-type ingredients with 4 or more monomers, such as the ingredients in this report, are named "Polyurethane-x".¹

Several precursors and moieties of these polymers have been reviewed by the CIR Panel.²⁻²⁶

Table 2 lists the previously reviewed ingredients and connects them to the relevant polyurethanes in this report. Other chemicals, including cosmetic ingredients which have not been reviewed by the Panel but are precursors or moieties of the polyurethanes in this safety assessment are listed in Table 3. The diisocyanate monomers used in the manufacturing of polyurethanes are listed separately in Table 4. These polyurethane ingredients are copolymers, each of which is synthesized, in part, from isocyanate analogs.^{27,28} Exposure to diisocyanates in the work place is one of the leading causes of occupational asthma and related issues; diisocyanates have also been associated with irritant and allergic contact dermatitis, as well as skin and conjunctival irritation. The Panel has reviewed hexamethylene diisocyanate (HDI) polymers, which are polymers (polyurethanes) also derived from isocyanates, and found that 17 of these ingredients are safe in cosmetics in the present practices of use and concentration, and that the available data are insufficient to make a determination that 2 HDI polymers are safe (Table 2; the full reports on these and all ingredients are available on the CIR website: http://www.cir-safety.org/ingredients).²⁹

Data on polyurethanes that are not listed in the wINCI *Dictionary* as cosmetic ingredients have been included for potential supporting information (e.g., cosmetic use and inflammatory response).

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that CIR typically

evaluates, is provided on the CIR website (<u>http://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites; http://www.cir-safety.org/supplementaldoc/cir-report-format-outline</u>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

<u>CHEMISTRY</u>

Definition and Structure

The structures, definitions, and functions of the polyurethane ingredients in this safety assessment are provided in Table 1. Some of the definitions may give insight into the method of manufacture. Several of these polyurethane ingredients, as defined, are the polymers dispersed in water (e.g., Polyurethane-17, -35, -36, -58, -60, -61, -70, -71, and -72).¹ Other polyurethanes may be supplied as dispersions (in water or other solvents), as indicated in ingredient specifications (e.g. Polyurethane-1, 14, -21, -28, -39 -42, and -69).³⁰⁻³⁴

The polyurethane ingredients in this report are copolymers containing carbamate (i.e., urethane) linkages. Polyurethanes are formed by reacting a polyol (e.g., a glycol) with a diisocyanate or a polyisocyanate. These polyurethane copolymers are a highly heterogeneous group of structures created from diverse diisocyanate, glycol, and carboxylic acid monomers. Representative structure motifs of three different urethane copolymers are depicted in Figure 1.




Figure 1. Examples of monomeric linkages in these urethane copolymers

Physical and Chemical Properties

Chemical and physical properties are provided in Table 5.

Some of the polyurethanes are linear polymers, but when multi-functional monomers (e.g., glycerin) are used as reactants, branched or cross-linked structures are probable. The degree of polymerization of these ingredients can be controlled to obtain a product having a desired functionality, such as rheology modifier. Accordingly, the molecular weights and molecular volumes of these ingredients could vary widely, unless otherwise noted in specifications. These polymers, by virtue of their monomers, contain both hydrophilic and hydrophobic groups. The ratio of hydrophilic and hydrophobic groups may vary within one ingredient name. Estimating some of the chemical and physical properties of these ingredients is

challenging in the absence of ingredient-explicit specifications. These ingredients potentially can range from liquid to solid and soluble to insoluble. Aside from the potential presence of a diisocyanate or end-capping agent residue, these ingredients are likely to be similar to unmodified polyurethane-type polymers.

Polyurethane-11

Polyurethane-11 is reported to have a mean molecular weight > 100,000 daltons (Da), with no fractions < 1000 Da.³⁵

Polyurethane-14

Based on the monomer composition and general hydrophobic properties of Polyurethane-14, it is not expected to be significantly soluble in water.³³ It is not expected to undergo significant hydrolysis within a pH range of 4 to 9. Polyurethane-14 partitions primarily in the organic phase in octanol-water separation systems.

Polyurethane-21

Polyurethane-21 is stable at a pH range of 7 to 11, but is not stable below pH 7.³²

Polyurthane-28

Polyurethane-28 is reported to have a mean molecular weight > 30,000 Da with no molecules < 1000 Da.^{34} This ingredient is reported to be stable at 5 to 50°C for 3 years under storage conditions.

Polyurethane-35

Based on the high mean molecular weight (> 1000 Da) and predominantly hydrophobic structure, Polyurethane-35 is expected to have low solubility in water.³⁶ This polymer is stable under normal environmental conditions and will not degrade in cosmetic products at 5% to 15%.

Polyurethane-42

Polyurethane-42 is reported to have a mean molecular weight of > 36,000 with no molecules < 1000 Da.³⁴ This ingredient is reported to be stable at 5 to 50°C for 3 years under storage conditions.

Polyurethane-60

A supplier reported that Polyurethane-60 is supplied as an aqueous, low viscosity, anionic dispersion polycarbonate-polyurethane.³⁷ The mean molecular weight of Polyurethane-60 is > 50,000 Da.

Polyurethane-61

A supplier reported that Polyurethane-61 is supplied as an aqueous, low viscosity dispersion of an aliphatic polyester-polyurethane.³⁸ The mean molecular weight of Polyurethane-61 is > 50,000 Da.

Polyurethane-62

A supplier reported that the particle size of Polyurethane-62 was 50 to $1000 \,\mu\text{m}$ and the mean molecular weight is > 70,000 Da.³⁹ Polyurethane-62 is stable under normal environmental conditions and yields no degradation products under normal conditions of use. Another supplier reports that the average molecular weight of Polyurethane-62 is approximately 100,000 Da.⁴⁰

Polyurethane-69

The average total molecular weight of Polyurethane-69 is > 3400 Da.³⁴ Low molecular weight fractions (< 1000 Da) were detected at 4%. Polyurethane-69 is stable for 16 weeks at 5, 25, and 50°C in normal storage conditions; there is no formation of high molecular weight crosslinked fractions and no depolymerization is detected.

Method of Manufacture

In general, polyurethanes are formed by reacting a polyol (e.g., a glycol) with a diisocyanate or polyisocyanate. Table 6 cites the methods of manufacture of individual polyurethanes.

Infrared spectroscopy is typically used to make sure the reaction is complete and that no diisocyanates are present.³⁵

Impurities/Constituents

Table 7 cites the polyurethanes that are reported to commonly be supplied, in tradename mixtures, as suspensions or solutions. Such suspensions typically include water and cyclopentasiloxane. However, preservatives, such as methylisothiazolinone (MI), and neutralizing agents may also be included in the suspension. ^{33,34,36-38,41} The non-polyurethane components of these tradename mixtures are not impurities or constituents of the ingredients in this report. Thus, their safety is assessed elsewhere. In 2014, the Panel concluded that MI is safe for use in rinse-off cosmetic products at concentrations up to 100 ppm and safe in leave-on cosmetic products when they are formulated to be non-sensitizing, which may be determined based on a quantitative risk assessment (QRA).⁴²

A supplier reports that Polyurethane-36, -60, and -61, which are supplied as dispersions in water, are reported to be

free from other solvents and isocyanate groups; residual isocyanates are expected to react with water in the dispersion and form polyureas.^{37,38,41}

Polyurethane-11

Polyurethane-11 is reported to contain no residual isocyanates since free isocyanates react with water.³⁵

Polyurethane-28, -42, and -69

Polyurethane-28, -42, and -69 are reported to contain no detectable residual isophorone diisocyanate (IPDI; a monomer used in their synthesis), as determined by high-performance liquid chromatography-mass spectrometry (HPLC-MS; detection limit 5 ppm).³⁴

Polyurethane-59

Polyurethane-59 is reported to contain no detectable residual ethylene oxide (detection limit < 1 ppm), dioxane (< 10 ppm), formaldehyde (< 1 ppm), and HDI (< 20 ppm).⁴³

Polyurethane-62

Polyurethane-62 is reported to contain no detectable residual unreacted isocyanate (HDI; a monomer used in their synthesis). 40

Polyurethane-2, -17, -29, -33, -40, -60, and -61

4,4'-Diaminodiphenylmethane (MDA) is classified as a carcinogen and is used in the production of methylene diphenyldiisocyanate (MDI).⁴⁴ MDI, or an analog thereof (E.G., saturated methylene diphenyldiisocyanate (SMDI)), is a monomer component of some of the polyurethanes in this safety assessment (e.g., Polyurethane-2, -17, -29, -33, -40, -60, and -61).¹ In a study to determine the safety profile of MDI in consumer products, no residual MDA was detected in the resultant production of MDI.⁴⁴ Furthermore, any remaining MDA would be expected to be further reduced when MDI is polymerized in the manufacture of polyurethanes.

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this assessment is evaluated based on data received from the United States (U.S.) Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in FDA's Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetic industry in response to a survey, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

According to VCRP survey data received in 2017, Polyurethane-11 was reported to be used in 315 formulations, with 303 uses reported in leave-on formulations and 12 uses in rinse-off formulations (Table 8).⁴⁵ The additional ingredients with reported uses in the VCRP were each reported to have uses in 33 or fewer formulations.

The VCRP has an entry for "polyurethane" with 17 uses in a pattern similar to the polyurethanes in this safety assessment. It is unknown to what extent, if any, "polyurethane" is the same as or similar to, one or more of the polyurethane ingredients in this safety assessment. Since the composition of this ingredient is unknown, this ingredient will not be further addressed in this safety assessment.

The results of the concentration of use survey conducted by the Council in 2016 indicate that Polyurethane-1 has the highest reported maximum concentration of use; it is used at up to 15% in nail products.⁴⁶ The highest maximum concentration of use reported for products resulting in leave-on dermal exposure is 7.5% Polyurethane-33 in the category of other skin care preparations.

In some cases, uses were reported to the VCRP, but concentrations of use data were not provided. For example, Polyurethane-7 was reported to be used in 14 cosmetic formulations, but no use concentration data were reported. In other cases, no uses were reported to the VCRP, but concentration of use data were received from industry; for example, Polyurethane-10 had no reported uses in the VCRP, but use concentrations in the categories of mascara; tonics, dressings, and other hair grooming aids; and foundations were provided in the industry survey. Therefore, it should be presumed there is at least one use in every category for which a concentration is reported.

The ingredients not in use according to the VCRP and industry survey are listed in Table 9.

Polyurethane-1, -2, -10, -11, -14, -33, -34, -35, and -40 were reported to be used in products that are applied around the eye; the highest reported concentration of use was 7%, which was for Polyurethane-35 in mascara. Polyurethane-11, -15, and -34 were reported to be used in products that may be ingested and come in contact with mucous membranes; the highest reported concentration of use was 2.9%, which was for Polyurethane-34 in lipsticks.

Several of the polyurethanes are used in cosmetic sprays and could possibly be inhaled. Polyurethane-1, -6, -11, -14, -18, -24, -33, and -34 were reported to be used in spray products; the maximum reported concentration for a spray product was 6% Polyurethane-6 in pump hair sprays. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters > $10 \,\mu$ m.⁴⁷⁻⁵⁰ Therefore, most droplets/particles incidentally inhaled

from cosmetic sprays would be deposited in the nasopharyngeal and bronchial regions and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.^{47,49} Polyurethane-2, -7, -11, and -15 were reported to be used in powders; the highest maximum reported concentration was at up to 3.2% Polyurethane-11. Conservative estimates of inhalation exposures to respirable particles during the use of loose-powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.⁵¹⁻⁵³

In Europe the amount of residual trialkylamines is limited to 2.5% in ready-for-use preparations in the category of leave-on products (which may be residuals in Polyurethane-17 and -21).^{54,55} Also, trialkylamines are further limited in that they are not to be used with nitrosating systems, have a maximum secondary amine content of 0.5%, have a maximum nitrosamine content of 50 μ g/kg, have a minimum purity of 99%, and must be kept in nitrite-free containers.

The National Industrial Chemical Notification and Assessment Scheme (NICNAS) of Australia determined that there is negligible concern to public health when Polyurethane-14 is used as a hair fixative agent in hair care products such as pump sprays and hair gel formulations at concentrations up to 6%.³³ NICNAS also determined that Polyurethane-35 and -62 were not considered to pose an unreasonable risk to the health of workers and the public.^{36,39}

Polyurethane-11 is reported to be used to coat cosmetic glitter.³⁵

Non-Cosmetic

In the U.S., polyurethanes may come in contact with food as direct and indirect food additives, and in single use and repeated use food containers. [21 CFR 174.5; 21 CFR 175.105; 21 CFR 176.170; 21 CFR 177.1210; 21 CFR 177.1390; 21 CFR 177.1395; 21 CFR 177.1680; 21 CFR 177.2600] Polyurethanes used in food packaging adhesives and polyurethane resins may not contain 4,4'-methylenebis (2-chloroanaline; or saturated methylene diphenyldiisocyanate (SMDI)). [21 CFR 189.280]

Polyurethanes may be used in ear, nose and throat medical devices, and in general and plastic surgery devices (e.g., silicone gel-filled breast prosthesis and occlusive wound dressing). [21 CFR 874.3695; 21 CFR 878.3540; 21 CFR 878.4020]

A supplier states that Polyurethane-36, -60, and -61 are not in compliance for use in food contact adhesives according to FDA regulations.^{37,38,41}

The FDA stipulates that polyurethane resins that are used in adhesives that may come in contact with food must be produced by one of four methods. 1) Reacting diisocyanates with one or more of the listed polyols or polyesters (this is a large list and is not provided here; an abbreviated list of monomers and precursors are provided in Table 10). 2) Reacting the chloroformate derivatives of one or more of the listed polyols or polyesters with one or more of the polyamines listed in Table 10. 3) Reacting toluene diisocyanate or 4,4'-methylenebis(cyclohexylisocyanate), also called saturated methylene diphenyldiisocyanate (SMDI), with either one or more of the listed polyols or polyesters listed in Table 10 and with either *N*-methyldiethanolamine and dimethyl sulfate or dimethylolpropionic acid and triethylamine, or a fumaric acid-modified polypropylene glycol or fumaric acid-modified tripropylene glycol, triethylamine, and ethylenediamine. 4) Reacting *meta*-tetramethylxylene diisocyanate with one or more of the listed polyols and polyesters (not listed here; Table 10) and with dimethylolpropionic acid and triethylaminoethanol, 2-dimethylamino-2-methyl-1-propanol, and/or 2-amino-2-methyl-1-propanol. [21 CFR 175.105]

Polyurethane-36 is exempt from the Toxic Substances Control Act (TSCA) Inventory listing requirements under the provisions of the TSCA Polymer Exemption.³³ [40 CFR 723.250] The CFR citation is the exemption for polymers, so it is likely that many of the polymers in this report are exempt from TSCA.

Polyurethane foam or porous polyurethane films are used to make wound dressings.⁵⁶⁻⁵⁸ Polyurethane prostheses are being developed for soft tissue scaffolds of blood vessels and tissues of the cardiovascular system; some of these are impregnated with drugs to control smooth muscle cell proliferation.⁵⁹ Polyurethanes are used to coat medical implants, including percutaneous leads, catheters, tubing, and intra-aortic balloons.^{60,61} Polyurethane has been used as a coating on breast implants.⁶²

Sprayed polyurethane foam is used for roofing material and other protective applications such as truck bed liners.⁶³

TOXICOKINETIC STUDIES

Toxicokinetic studies were not found in the published literature and no unpublished data were submitted.

TOXICOLOGICAL STUDIES

Acute Dose Toxicity

Acute dermal toxicological studies were not found in the published literature and no unpublished data were submitted.

Oral

Polyurethane-1

The oral LD_{50} of Polyurethane-1 in rats was reported to be > 2000 mg/kg.³⁰ The test was conducted in accordance with the Organisation for Economic Co-operation and Development test guideline (OECD TG) 423 (Acute Oral toxicity).

Polyurethane-35

The oral LD_{50} of Polyurethane-35 in rats was reported to be 4890 mg/kg.³⁶ The test was conducted in accordance with the OECD TG 423. No further details were provided.

Polyurethane-39

The oral LD_{50} for Polyurethane-39 was reported to be > 2000 mg/kg for female Sprague-Dawley rats (n = 6).³¹ The test substance was administered by gavage and the rats were observed for 14 days after dosing.

Inhalation

Polyurethane-1

The inhalation no-observed-adverse-effects-concentration (NOAEC) for Polyurethane-1 (tested at 0, 3, 10, 30, and 100 mg/m³) was 3 mg/m³ when administered to rats (n = 8) for 6 h/day for 5 days.³⁰

Polyurethane-14

Sprague Dawley rats (n = 5/sex) were exposed to Polyurethane-14 (9.6% in 55% ethanol) for 4 h in a whole body inhalation chamber at 110 mg/m³ Polyurethane-14 and 964,000 mg/m³ ethanol as a liquid droplet aerosol.⁶⁴ The mean aerodynamic diameter of the particles was $1.9 \pm 3.21 \,\mu$ m. There were no mortalities during the experiment or during the 14-day observation period. Clear nasal discharge was observed in one male following exposure. No toxicologically significant clinical findings were observed. There were no remarkable body weight changes or observations at necropsy. The LC₅₀ of Polyurethane-14 was reported to be > 110 mg/m³.

Short-Term Toxicity Studies

Short-term dermal and oral toxicity studies were not found in the published literature and no unpublished data were submitted.

Inhalation

Polyurethane-14

Sprague Dawley rats (n = 5/sex) were exposed to Polyurethane-14 (9.6% in 55% ethanol) 6 h/day for 14 days in a whole body inhalation chamber at 10, 30, and 100 mg/m³ Polyurethane-14 and 964 ppm ethanol as a liquid droplet aerosol.⁶⁵ There were no mortalities during the exposure period. At necropsy, pallor was observed in the lungs of one male and one female in the 30 mg/m³ group; this finding was consistent with histopathologic observations of alveolar histiocytosis and was considered an effect of exposure to the test material. The mean absolute lung weights were increased in both sexes of the 100 mg/m³ group and the females of the 30 mg/m³ group; mean relative lung weights were increased in both sexes in the 30 and 100 mg/m³ groups. The increased lung weights were considered an effect of exposure to the test material and correlated with the increased incidence and severity of alveolar histiocytosis. The diffuse alveolar histiocytosis, observed in the lungs of the rats in the 30 and 100 mg/m³ groups, increased in severity with increased exposure. Multifocal, minimal alveolar histiocytosis was observed in the lungs of some of the rats in the control and 10 mg/m³ groups and was not considered to be an effect of exposure to the test material.

Subchronic Toxicity Studies

Subchronic oral and dermal toxicity studies were not found in the published literature and no unpublished data were submitted.

Inhalation

Polyurethane-1

The inhalation NOAEC for Polyurethane-1 (tested at 0, 1, 3, and 10 mg/m³) was 1 mg/m³ when administered to rats (n = 20) for 6 h/day for 65 exposures over 90 days.³⁰ The experiment was conducted in a head/nose apparatus and the recovery period was 3 months.

Polyurethane-14

Sprague Dawley rats (n = 15/sex) were exposed to Polyurethane-14 (9.6% in 54.9% ethanol neutralized with adenosine monophosphate) 6 h/day, 5 days/week, for 90 days (66 doses) in a nose-only inhalation chamber at 1.17 ± 0.3 , 5.3 ± 1.1 , and $40.6 \pm 4.8 \text{ mg/m}^3$ (50, 147, 320 ppm, respectively) Polyurethane-14 and 964 ppm ethanol as a liquid droplet aerosol.⁶⁶ The particle aerodynamic diameters were 1.5 ± 2.7 , 1.4 ± 2.1 , and $1.9 \pm 2.2 \mu m$ (\pm geometric standard deviation), which resulted in a respirable percentage of 97.2%, 99.6%, and 98.3%, respectively. After exposure, 5 rats/sex were allowed to recover for 13 weeks.

There were no test material-related deaths or clinical observations. There were no toxicologically significant effects on mean body weights, body weight gains, feed consumption, microscopic organ evaluations (except the lung and lymph nodes), or on hematology or serum chemistry parameters. In the air and ethanol controls and the low dose group, a background syndrome was present, which was described as concurrent mild perivascular inflammatory cell infiltrate and/or

subacute inflammation (mixed cell type) with interstitial pneumonia. This pattern was distinguishable from test-article induced responses. Exposure to Polyurethane-14 in the 5.3 and 40.6 mg/m³ groups resulted in a low incidence of macroscopic findings, such as white areas in the lungs and enlarged lymph nodes, a dose-dependent increase in lung weights, accumulation of foamy alveolar macrophages, interstitial pneumonia, and acute inflammation (alveolar neutrophils) in the lung. The incidence and severity of the above findings generally decreased in the recovery animals, indicating partial recovery. A few 1.2 mg/m³ and greater numbers of 5.3 and 40.6 mg/m³ exposed rats had foamy macrophage accumulations in the mediastinal and/or tracheobronchial lymph nodes. Accumulation of foamy macrophages in the lung or lymph node is considered a normal physiological response necessary to remove particles from the lung, and was not considered to be an adverse health effect. Based on the results of this study, the no observed adverse effect level (NOAEL) was 1.2 mg solids/m³. The lack of primary parenchymal toxicity and progressive lesions demonstrated that Polyurethane-14 is a polymer of low toxicity.⁶⁶

Chronic Toxicity Studies

Chronic toxicity studies were not found in the published literature and no unpublished data were submitted.

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART) STUDIES

DART studies were not found in the published literature and no unpublished data were submitted.

GENOTOXICITY STUDIES

In Vitro

Genotoxicity studies are summarized in Table 11.

Polyurethane-1 (30%) was not mutagenic in an Ames test when tested at up to 16,000 μ g/plate, both with and without metabolic activation.³⁰ Polyurethane-28 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay conducted in accordance with OECD TG 471 (Bacterial Reverse Mutation Test) using *Salmonella typhimurium* and *Escherichia coli*.³⁴ Polyurethane-35 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay conducted in accordance with OECD TG 471.³⁶ Polyurethane-42 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay conducted in accordance with OECD TG 471.³⁶ Polyurethane-42 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay conducted in accordance with OECD TG 471 using *S. typhimurium* and *E. coli*.³⁴ In an Ames mutagenicity test of Polyurethane-62 (up to 5000 μ g/plate) using *S. typhimurium* and *E. coli*, no cytotoxicity or precipitation was observed with or without metabolic activation and there were no significant increases in the frequency of revertant colonies.⁶⁷

In Vivo

In vivo genotoxicity studies were not found in the published literature and no unpublished data were submitted.

CARCINOGENICITY STUDIES

Carcinogenicity studies were not found in the published literature and no unpublished data were submitted.

OTHER RELEVANT STUDIES

Inflammatory Response

Male Swiss albino mice (n = 6) received a polyurethane nanoparticle solution (0, 2, 5, or 10 mg/kg in saline) by gavage daily for 10 days.⁶⁸ The polyurethane tested was manufactured with a natural triol, diisocyanate, and olive oil that were added to a solution of Polysorbate 80 while stirring at room temperature. The polyurethane particles had a diameter of 249 ± 5.7 nm and a polydispersity index (PDI) of 0.3 ± 0.04 . All mice survived the study and there were no behavioral changes observed. At necropsy, there were no differences in body weights or organ weights among the groups. There was increased visceral fat accumulation in the mice in all treatment groups compared to controls. The lungs of mice in the 5 and 10 mg/kg/day groups (4 and 6 mice, respectively) showed inflammation, and inflammatory infiltrate was observed in all treatment groups. The kidneys of mice in the 5 and 10 mg/kg/day groups (5 and 6 mice, respectively) showed glomerular necrosis and glomerular atrophy. Histological examination of the adipose tissue did not reveal any alterations in morphology in any group. Oral polyurethane administration induced an increase in alanine aminotransferase (ALT) levels (58 ± 7.7, 69 ± 15, and 78 ± 4.5 IU/L in the 2, 5, and 10 mg/kg groups, respectively, versus control mice 34 ± 3.5 IU/L). Mice in the 5 and 10 mg/kg groups also showed an increase in alkaline phosphatase activities (ALP; 20 ± 4 and 24 ± 2 IU/L, respectively, versus controls, 8.5 ± 1.7 IU/L). Hematological evaluation revealed no changes in any parameter. There was an increase in TNF- α level (approximately 80-fold) in mice in the 10 mg/kg group. The authors concluded that oral administration of polyurethane an inflammatory response in mice.

DERMAL IRRITATION AND SENSITIZATION STUDIES Irritation

In Vitro

Polyurethane-35

In an in vitro dermal corrosion assay conducted in accordance with OECD TG 431 (In Vitro Skin Corrosion: Human Skin Model Test), Polyurethane-35 was not corrosive.³⁶ No further information was provided.

Polyruethane-62

An EpiSkin assay using the reconstructed human epidermis (RhE) model conducted in accordance with OECD TG 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method) was conducted on Polyurethane-62 (tested without trideceth-6 solvent; not specified if tested in water or other neutral solvent).⁶⁷ Polyrurethane-62-treated cells had a 95% survival rate. Survival greater than 50% is considered negative for dermal irritation. The control had the expected result.

Animal

Polyurethane-1

Polyurethane-1 (30% in water and ethanol; 0.5 mL) was not a dermal irritant in rabbits when exposed for 4 h under semi-occlusion.³⁰

Polyurethane-35

In a skin irritation study conducted in accordance with OECD TG 404 (Acute Dermal Irritation/Corrosion), Polyurethane-35 (40% in water) was slightly irritating to the skin of rabbits (n = 3).³⁶ The author noted that the removal of the patch was not possible without altering the response or the integrity of the epidermis in one rabbit. All irritation effects were reversible within 7 days. The irritant effects were not sufficient to warrant classification as a skin irritant. No further information was provided.

Polyurethane-39

Polyurethane-39 was not irritating to rabbits (n = 2 males, 1 female) when applied under semi-occlusion.³¹ The experiment was conducted in accordance with OECD TG 404.

Human

Polyurethane-14

In a cumulative irritation assay, subjects (n = 29) were topically exposed to Polyurethane-14 (9.6% in 55% ethanol; 0.2 mL), 55% ethanol, distilled water, or sodium lauryl sulfate (0.075%) for 21 days.⁶⁹ Exposure was under semi-occlusive conditions for days 1 through 9; exposure was changed to semi-open due to irritation observed in the polyurethane and ethanol control groups. Scoring for cumulative irritation was performed every 24 h immediately prior to reapplication or until excessive irritation was noted. Polyurethane-14 produced erythema and papules in three subjects by the fourth application. After changing to semi-open patches, an additional subject was observed with erythema and papules on day 19. Under identical conditions, the ethanol control produced erythema and papules in three subjects by the third application. No to very slight erythema was observed at the majority of sites treated with Polyurethane-14 or ethanol. Sites treated with distilled water elicited a very low response. Distilled water and 0.1% sodium lauryl sulfate produced the expected results. The cumulative scores were 232 (Polyurethane-14 solution), 208 (ethanol solution), 13 (water), and 338 (sodium lauryl sulfate) out of a possible 1575. Under the conditions of the study, both 9.6% Polyurethane-14 and the ethanol control produced mild to moderate irritation in a few subjects, with no differences in the responses to these two test articles.

Polyurethane-21

In a human dermal irritation study (n = 10), Polyurethane-21 was applied twice to scarified skin for 24 h using a chamber device with a 12 mm well.⁷⁰ Saline was used as the control. The test substance had an average irritation score of 0.50 (out of 4); the saline control had an average score of 0.55. The irritation potential of Polyurethane-21 was low.

Sensitization

In Vitro

Polyurethane-62

A Direct Peptide Reactivity Assay (DPRA) measuring reactivity (percent depletion) of cysteine and lysine peptides by liquid chromatography with a UV detector (LC-UV) was conducted on Polyrurethane-62 (tested without trideceth-6 solvent; not specified if tested in water or other neutral solvent).⁶⁷ This assay was conducting in accordance with the OECD Draft Proposal for Guideline, *In Chemico* Skin Sensitization (Direct Peptide Reactivity Assay). The mean depletion rates were 0.02% for Polyrurethane-62 and 78.04% for the positive control. Depletion less than 6.38% is considered to have no, or minimal, reactivity and is predicted to be negative for dermal sensitization. The control had the expected result.

Animal

Polyurethane-1

Polyurethane-1 (30% in water and ethanol) was not sensitizing to guinea pigs (n = 20; control = 10) in a Buehler assay.³⁰ The induction was conducted at 10% (approximately 3% Polyurethane-1 in distilled water) and the challenge at 5% (1.5%). The induction and challenge applications were in contact with the skin for 6 h.

Polyurethane-14

A guinea pig maximization test was conducted in accordance with OECD TG 406 (Skin Sensitization) on Polyurethane-14 (23.4% solids in 27% ethanol).⁷¹ The guinea pigs (n = 10/sex; control = 5/sex) were injected with 0.1 mL of a 1% solution of Polyurethane-14 with and without Freund's Complete Adjuvant. After pretreatment with 10% sodium lauryl sulfate, an 8 cm²-patch of filter paper saturated with the test article was applied topically for 48 h. The challenge was applied to virgin sites. A 4-cm² patch of filter paper saturated with the test material was applied topically for 24 h. The application sites were evaluated for erythema 48 and 72 h after application. Moderate to intense redness was observed after the intradermal injection, which was reduced to scabbing for the remainder of the induction period. No erythema was observed after challenge with the test material or the control. Under the described test conditions, the test material did not cause a sensitization reaction in guinea pigs.

Polyurethane-35

In Buehler and maximization tests conducted in accordance with OECD TG 406, Polyurethane-35 showed no evidence of causing sensitization.³⁶ No further information was provided.

Polyurethane-39

Polyurethane-39 (0, 3%, 10%, and 30% in 70% ethanol in water) was not sensitizing to mice (n = 5) in a local lymph node assay (LLNA).³¹

Human

Human repeated insult patch tests (HRIPT) of polyurethanes are summarized in Table 12.

Mascaras containing Polyurethane-1 (28.5% and 30%) were not sensitizing in HRIPTs.^{72,73} Polyurethane-14 (9.61% solids) caused mild erythema in a few subjects but did not demonstrate a hypersensitivity response.⁷⁴ Polyurethane-21 (tested at 21% and 35% solids) was not a sensitizer.^{75,76}

OCULAR IRRITATION STUDIES

In Vitro

In vitro ocular irritation assays are summarized in Table 13.

A mascara containing Polyurethane-1 (30%) was not predicted to be an ocular irritant in a neutral red release assay (NRR), chorioallantoic membrane of the embryonic hen's egg assay (HET-CAM), and reconstituted human epithelial culture (REC) assays.⁷⁷ Considering the 3 assays above, the estimated Draize classification of the test material is a slight irritant with a score of 0 to 15. Another mascara containing Polyurethane-1 (30%) was tested for ocular irritation in a HET-CAM assay (tested at 50%; final concentration 15%), BCOP, and EpiOcularTM assay (tested at 20%; final concentration 6%), and was predicted to not be an ocular irritant.⁷⁸⁻⁸⁰ In an EpiOcular assay, a product containing Polyurethane-14 (10%) was tested at 20% (final concentration of Polyurethane-14 was 2%); the estimated Draize ocular irritation score of the test material at 100% was predicted to be 0 and Polyurethane-14 was predicted to be a non-irritant.⁸¹ Polyurethane-21 (100%; 35% solids) was predicted to not be an ocular irritant in HET-CAM and BCOP assays.^{82,83} Polyurethane-42 was predicted to be a moderate irritant in a HET-CAM assay and a non-irritant in a BCOP assay.³⁴ Polyurethane-62 was predicted to not be an ocular irritation in an EpiOcular stage.⁶⁷

Animal

Polyurethane-1

Polyurethane-1 (30% in water and ethanol; 0.5 mL) was not an ocular irritant to rabbits.³⁰ The test was conducted according to OECD TG 405 (Acute Eye Irritation/Corrosion).

Polyurethane-35

In an eye irritation study conducted in accordance with OECD TG 405, two of the rabbits (n = 3) exhibited redness in the conjunctivae in the treated eye of one rabbit 1 h after instillation of Polyurethane-35, and the remaining rabbit exhibited these effects in 1 treated eye 24 h after instillation.³⁶ All irritation responses were reversible within 48 h and were not sufficient to warrant classification of the polymer as an eye irritant.

Polyurethane-39

Polyurethane-39 (approximately 30% solids) was not irritating when instilled into the eyes of rabbits.³¹ The test was

Human

A 4-week use study of two mascaras containing Polyurethane-1 (30% and 28.5%) was conducted in subjects (n = 38) that either wore contact lenses or were self-assessed as having sensitive eyes.⁸⁴ Trace increases in redness of the palpebral conjunctivae were observed in three subjects during weeks 2 and/or 4; a trace increase in bulbar conjunctival redness was observed in one subject in week 2. There were no reports of subjective irritation. There were no increases in lacrimation or eyelid inflammation. There were no changes in visual acuity or corneal tissue integrity. Both mascaras were found to be non-irritating.

SUMMARY

This is a review of the available scientific literature and unpublished data relevant for assessing the safety of polyurethanes as used in cosmetics. According to the wINCI *Dictionary*, the functions of these 66 ingredients include artificial nail builders, binders, film formers, hair fixatives, plasticizers, and surface modifiers. The polyurethane ingredients in this report are copolymers, which comprise carbamate (i.e., urethane) linkages within the respective polymer backbone.

Several of these polyurethane ingredients, as defined, are the polymers dispersed in water (e.g., Polyurethane-17, -35, -36, -58, -60, -61, -70, -71, and -72). Polyurethane ingredients for which molecular weights were reported were all greater than 1000 Da.

The ingredients in this report are copolymers, each of which is synthesized, in part, from isocyanate analogs. Exposure to diisocyanates (monomers of the polymers in this report) in the work place is one of the leading causes of occupational asthma.

Polyurethane-36 and -60 are reported to be free of solvents and isocyanate groups; residual isocyanates are expected to react with water in trademark mixture dispersions and form carbonic acids. As supplied, a tradename mixture of Polyurethane-36 contains approximately 1.0% to 1.5% phenoxyethanol as a preservative and approximately 1.0% to 1.5% trimethylamine as a neutralizing agent. In tradename mixtures thereof, Polyurethane-60 and -61 contain approximately 0.0075% MI and 0.0075% benzisothiazolinone as preservatives, and approximately 1.3% and 1.5% by weight, respectively, dimethylethanolamine as a neutralizing agent. However, these non-polyurethane ingredients are components of the certain tradename mixtures, not components of the ingredients under review in this report. Accordingly, their safety is evaluated elsewhere. Polyurethane-62 is reported to contain no detectable residual unreacted isocyanate monomer (HDI).

According to VCRP survey data received in 2017, Polyurethane-11 was reported to be used in 315 formulations, including 303 in leave-on formulations and 12 in rinse-off formulations. The other ingredients that had reported uses were reported to be used in 33 or fewer formulations. The results of the concentration of use survey conducted by the Council in 2016 indicate that Polyurethane-1 has the highest reported maximum concentration of use; it is used at up to 15% in nail products. The highest maximum concentration of use reported for products resulting in leave-on dermal exposure is 7.5% Polyurethane-33 in the category of other skin care preparations.

The oral LD_{50} of Polyurethane-1 in rats was reported to be > 2000 mg/kg. The oral LD_{50} of Polyurethane-35 in rats was reported to be 4890 mg/kg. The oral LD_{50} for Polyurethane-39 was reported to be > 2000 mg/kg for rats.

The inhalation NOAEC for Polyurethane-1 was 3 mg/m^3 when administered to rats for 6 h/day for 5 days. The inhalation LC₅₀ of Polyurethane-14 for rats for 4 h was 110 mg/m³ in a whole body chamber.

The oral administration of polyurethane particles at 5 and 10 mg/kg/day for 10 days generated inflammation in mice. The polyurethane particles had a diameter of 249 ± 5.7 nm and a PDI of 0.3 ± 0.04 . There was increased visceral fat accumulation in the treated mice in all groups (2, 5, 10 mg/kg/d) compared to controls. The lungs of mice in the 5 and 10 mg/kg/day groups showed inflammation, and inflammatory infiltrate was observed in all treatment groups.

Polyurethane-14 caused alveolar histiocytosis in rats exposed for 6 h/day for 14 days in a whole body inhalation chamber at 30 and 100 mg/m³ in a dose-dependent manner. Multifocal, minimal alveolar histiocytosis was observed in the lungs of some of the rats in the control and 10 mg/m³ groups and was not considered to be an effect of exposure to Polyurethane-14.

Polyurethane-1 (30%) was not mutagenic in an Ames test; Polyurethane-1 was tested up to 16,000 μ g/plate in both SPT and PIT assays, both with and without metabolic activation. Polyurethane-28 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay conducted in accordance with OECD TG 471 using *S. typhimurium* and *E. coli*. Polyurethane-35 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay. Polyurethane-42 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay. Polyurethane-42 (concentration not specified) was not mutagenic in a bacterial reverse mutation assay using *S. typhimurium* and *E. coli*. In an Ames mutagenicity test of Polyurethane-62 (up to 5000 μ g/plate) using *S. typhimurium* and *E. coli*, no cytotoxicity or precipitation was observed with or without metabolic activation and there were no significant increases in the frequency of revertant colonies.

Polyurethane-35 and -62 were not corrosive to human skin cells in in vitro dermal corrosion assays.

Polyurethane-1 at 30% was not a dermal irritant in rabbits when exposed for 4 h under semi-occlusion. Polyurethane-39 was not irritating to rabbits when applied under semi-occlusion.

In a skin irritation study, Polyurethane-35 (40% in water) had a slight irritating effect to the skin of rabbits. All irritation effects were reversible within 7 days.

Polyurethane-62 was predicted to be non-sensitizing in a DPRA.

Polyurethane-1 was not sensitizing to guinea pigs in a Buehler assay. The induction was conducted at approximately 3% and the challenge at approximately 1.5%. In a guinea pig maximization test, Polyurethane-14 (23.4% solids) was not sensitizing. In Buehler and maximization tests, Polyurethane-35 (concentration not specified) showed no evidence of sensitization. Polyurethane-39 (up to 30%) was not sensitizing to mice in an LLNA.

In a cumulative irritation test, Polyurethane-14 (9.6% in 55% alcohol) was mildly to moderately irritating to human subjects and had similar results as ethanol (55%). In a human dermal irritation study, Polyurethane-21 had an average irritation score of 0.50 (out of 4); the saline control had an average score of 0.55. The irritation potential of Polyurethane-21 was low.

Mascaras containing 28.5% and 30% Polyurethane-1 did not demonstrate a potential for eliciting dermal irritation or sensitization in HRIPTs.

In an HRIPT of Polyurethane-21 (21% solids), no adverse reactions of any kind were observed during the course of the study. The study authors concluded that Polyurethane-21, as tested, was considered a non-primary irritant and a non-primary sensitizer. In an HRIPT of Polyurethane-21 (35% solids), no adverse reactions of any kind were observed during the course of the study. The study authors concluded that Polyurethane-21, as supplied, was considered a non-primary irritant and a non-primary sensitizer. In an HRIPT, Polyurethane-14 (10%) was not sensitizing and there were no adverse reactions observed at any time during the study. In another HRIPT, Polyurethane-14 (9.61% solids) was not sensitizing.

In in vitro tests of a mascara containing Polyurethane-1 at 30%, the test material was rated slightly cytotoxic in a NRR assay, HET-CAM assay, and a REC assay; when considering these three assays together, the authors concluded that the results might be equivalent to a Draize score of 0-15 (slightly irritating). Based on in vitro tests of another mascara containing Polyurethane-1 at 30%, the test substance was predicted to have practically no ocular irritation potential (HET-CAM assay and a BCOP assay). In EpiOcular assays, a product containing Polyurethane-14 (10%) and Polyurethane-62 were predicted to not be ocular irritants. Polyurethane-21 (100%; 35% solids) was predicted to not be an ocular irritant in HET-CAM and BCOP assays. Polyurethane-42 was found to be a "moderately irritant" in a HET-CAM assay and a non-irritant in a BCOP assay.

Polyurethane-1 at 30% was not an ocular irritant to rabbits. In an eye irritation study conducted with rabbits, the irritant effects were not sufficient to warrant classification of Polyurethane-35 as an eye irritant. Polyurethane-39 (approximately 30% solids) was not irritating when instilled into the eyes of rabbits.

In a 4-week use study with human subjects of two mascaras containing Polyurethane-1 (30% and 28.5%), the mascaras were found to be non-irritating.

DISCUSSION

The CIR Panel examined the available data, which included method of manufacture and impurity data; acute and repeated-dose oral and inhalation toxicity; genotoxicity; dermal and ocular irritation data; and sensitization data. These ingredients are mixtures of very large polymeric molecules. The assays for ocular and dermal irritation showed that there were no concerns that these ingredients would be irritating under the conditions of use. There is limited toxicity data for only 7 of these ingredients; the Panel relied heavily on the fact that these molecules are large and will not penetrate the epidermis, making systemic toxicity studies unnecessary.

Many of these polyurethanes are reported to be supplied, in tradename mixtures, as emulsions or in solutions with multiple non-polyurethane ingredients that may include sensitizers such as the preservative MI (e.g., as reported in some tradename mixtures containing Polyurethane-60 and -61), even though these preservatives may not be disclosed in the information provided by suppliers. Cosmetics manufacturers and formulators are advised to be aware of the presence of potentially sensitizing constituents in these ingredients, as supplied, and to avoid reaching levels of potential sensitizers that may be hazardous to consumers, especially when combining these ingredients with other ingredients that may contain sensitizers. The Panel recommended that a QRA be used to determine the levels needed to minimize sensitization in consumers.

The Panel noted that these polyurethanes contain monomers that could be of concern if there was significant residual monomer present. For example, inhalation of the HDI monomer can cause occupational asthma, hypersensitivity pneumonitis, rhinitis, and accelerated lung deterioration. The Panel noted that these polyurethane ingredients are heterogeneous in their structures and monomeric components. However, these ingredients are all large molecules and will not be readily absorbed through the skin. These polymers are expected to be stable and any residual monomers would be either washed away in manufacturing or, because the monomers are reactive, consumed in reaction with solution or formulations. The Panel was comfortable that there would not be any significant residual HDI (or other isocyanate analogs such as isophorone diisocyanate, saturated methylene diphenyldiisocyanate, 1-isocyanato-1-methylethylbenzene, or hexamethylene diisocyanate) or other monomers in these ingredients, as supplied for formulation. However, producers and formulators should continue to use current good manufacturing practices (cGMP) and avoid creating conditions where monomers could be released into solution or formulation.

The Panel noted that Europe restricts the amount of residual amines, which may be present as residuals from the manufacturing process in Polyurethane-17 and -21, to 2.5% in ready-for-use leave-on preparations. These amines are used in low concentrations. However, residual low-molecular-weight amines should be minimized in polyurethane ingredients to reduce risk of nitrosating reactions and should not be used in cosmetic products in which *N*-nitroso compounds can be formed.

Because these polyurethanes are commonly only supplied as tradename mixture emulsions or solutions (at 20% to 66%), there has been some confusion about the concentration of the polyurethanes in the safety data (e.g., was the concentration stated of the emulsion or the polyurethane in the emulsion). It was necessary to discern how the concentration of the polyurethane in each test was presented.

The Panel recognizes that there are data gaps regarding use and concentration of these ingredients. However, the overall information available on the types of products in which these ingredients are used and at the concentrations provided, indicate a pattern of use which was considered by the Panel in assessing safety.

The Panel discussed the issue of incidental inhalation exposure from body and hand products, and hair sprays. The limited data available from inhalation studies, including acute and short-term exposure data, suggest little potential for respiratory effects at relevant doses. The mean aerodynamic diameter of the tested particles of Polyurethane-14 was $1.9 \pm$ 3.21 µm. The Panel believes that the sizes of a substantial majority of the particles of these ingredients, as manufactured, are larger than the respirable range and/or aggregate and agglomerate to form much larger particles in formulation. Thus, the adverse effects reported using high doses of respirable particles in the inhalation studies do not indicate risks posed by use in cosmetics. These ingredients are reportedly used at concentrations up to 6% in cosmetic products that may be sprayed and up to 3.2% in loose powder products that may become airborne. The Panel noted that droplets/particles from cosmetic products would not be respirable to any appreciable amount. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. The Panel considered other data available to characterize the potential for polyurethanes to cause systemic toxicity, irritation, sensitization, and genotoxicity and noted the lack of systemic toxicity in acute oral exposure studies, little or no irritation or sensitization in multiple tests of dermal and ocular exposure, the absence of genotoxicity in multiple Ames tests, and the lack of irritation or sensitization in tests of dermal exposure. In addition, these ingredients are large macromolecules, are reported or predicted to be insoluble in water, and chemically inert under physiological conditions or conditions of use, which supports the view that they are unlikely to be absorbed or cause local effects in the respiratory tract. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at http://www.cirsafety.org/cir-findings.

CONCLUSION

The CIR Expert Panel concluded that the following ingredients are safe as used in cosmetics in the present practices of use and concentration described in this safety assessment:

Polyurethane-1	Polyurethane-19*	Polyurethane-41*	Polyurethane-58*
Polyurethane-2	Polyurethane-20*	Polyurethane-42*	Polyurethane-59*
Polyurethane-4*	Polyurethane-21*	Polyurethane-43*	Polyurethane-60*
Polyurethane-5*	Polyurethane-23*	Polyurethane-44*	Polyurethane-61*
Polyurethane-6	Polyurethane-24	Polyurethane-45*	Polyurethane-62*
Polyurethane-7	Polyurethane-25*	Polyurethane-46	Polyurethane-63*
Polyurethane-8	Polyurethane-26*	Polyurethane-47*	Polyurethane-64*
Polyurethane-9	Polyurethane-27*	Polyurethane-48*	Polyurethane-65*
Polyurethane-10	Polyurethane-28*	Polyurethane-49*	Polyurethane-66*
Polyurethane-11	Polyurethane-29*	Polyurethane-50*	Polyurethane-67*
Polyurethane-12*	Polyurethane-32*	Polyurethane-51*	Polyurethane-68*
Polyurethane-13*	Polyurethane-33	Polyurethane-52*	Polyurethane-69*
Polyurethane-14	Polyurethane-34	Polyurethane-53*	Polyurethane-70*
Polyurethane-15	Polyurethane-35	Polyurethane-54*	Polyurethane-71*
Polyurethane-16	Polyurethane-36*	Polyurethane-55*	Polyurethane-72*
Polyurethane-17*	Polyurethane-39	Polyurethane-56*	
Polyurethane-18	Polyurethane-40	Polyurethane-57*	


* Not reported to be in current use. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in this group.

TABLES

1 1 1 1	D C' '.'	
anie i	Definitions	idealized monomer structures, and functions of the ingredients in this safety assessment. ^{1, CIR Staff}
I abit I.	Dominions	

Table 1. Defi Ingredient	initions, idealized monomer structures, and functions of the ingredients in this safety assessment. ^{1, CIR Staff} Definition & Monomer	
CAS No.	Structures	Function(s)
Polyurethane-1	Polyurethane-1 is a copolymer of isophthalic acid, adipic acid, hexylene glycol, neopentyl glycol, dimethylolpropanoic acid [DMPA], and isophorone diisocyanate monomers. [Monomers:] isophthalic acid	Binder; film former; hair fixative
	hexylene glycol CH ₃	
	HO HO dimethylolpropanoic acid dimethylolpropanoic acid isophorone diisocyanate	
Polyurethane-2	Polyurethane-2 is a copolymer of hexylene glycol, neopentyl glycol, adipic acid, saturated methylene diphenyldiisocyanate (SMDI), and dimethylolpropanoic acid monomers. [Monomers:]	Film former
	HO hexylene glycol OH HO HO HO HO HO HO HO HO HO HO HO HO	
Polyurethane-4	dimethylolpropanoic acid Polyurethane-4 is a copolymer of PPG-17, PPG-34, isophorone diisocyanate and dimethylolpropanoic acid [DMPA] monomers. [Monomers:]	Film former
	$HO \begin{bmatrix} CH_3 \\ HO \end{bmatrix}_{17} HO \begin{bmatrix} CH_3 \\ HO \end{bmatrix}_{34} HO = 17$	
	HO HO HO HO HO HO HO HO	

Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment. ^{1, CIR State}	ff
Table 1. Definitions, idealized monomer subclures, and functions of the highedients in this safety assessment.	






Table 1. Definitions idealized monome	her structures, and functions of the ingredients in this safety assessment. ^{1, CIR St}	aff
Lable 1. Definitions, idealized monomic	ici su uctures, and functions of the ingredients in this safety assessment.	







Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}





polycaprolactonetriol






Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment. ^{1, CIR State}	ff
Table 1. Definitions, idealized monomer subclures, and functions of the highedients in this safety assessment.	




Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}





Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}







Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}








Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}








Table 1.	D efinitions	. idealized	monomer structures.	and functions	of the ingre	edients in	this safety	assessment. ^{1, CIR Staff}





Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}






Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}





Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}









Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}





Binder; film former






Table 1. Definitions, idealized monomer structures, and functions of the ingredients in this safety assessment.^{1, CIR Staff}

Ingredient	Definition & Monomer	
CAS No.	Structures	
Polyurethane-72 502761-95-7	Polyurethane-72 is a urethane polymer made by reacting hydrogenated acetophenone/oxymethylene copolymer with isophorone diisocyanate (IPDI), dimethylolpropanoic acid, and dimethyl MEA. The resulting polymer is dispersed in water. [Monomers/reactants:] $\left[\begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	Binder; film former; nail conditioning agent

Moiety	Conclusion; year	Relevant to	Referen
Acetic Acid	Safe as used; 2012	Polyurethane-26	22
Adipic Acid;	Safe as used; 2012	Polyurethane-1, -2, -5,	6
Hexanedioic Acid		-6, -7, -9, -11, -13, -15,	
		-17, -19, -21, -23, -33,	
		-34, -35, -40, -48, -61,	
		-63, -65, -70, -71	
Alkyl PEG Ethers	Safe when	Polyurethane-39, -62	23
Alkyl FEO Euleis	formulated to be	Foryureurane-59, -02	
	non-irritating; 2012		
Destadana Classel	U,	Delementhe and 1 2	3,5
Butylene Glycol,	Safe as used; 1985,	Polyurethane-1, -2,	
Hexylene Glycol	2006	-5, -6, -7, -17, -33	2
1,4-Butanediol; 1,5-	1,4-Butanediol-	Polyurethane-8, -11,	-
Pentadiol; Hexanediol	Insufficient Data;	-13, -21, -23, -24, -32,	
	1,5-Pentadiol and	-34, -35, -41, -46, -48,	
	Hexanediol-safe as	-49, -50, -51, -52, -53,	
	used; 2017	-55, -56, -57, -60, -61,	
		-63, -66, -70, -71	
1,2-Butanediol	Safe as used; 2012	Polyurethane-51, -54	10
Diethanolamine	Safe when	Polyurethane-10, -29,	15
	formulated to be	-46, -70	
	non-irritating; 2011		
Ethylhexylglycerin	Safe as used; 2013	Polyurethane-59	12
Glycine Soja (Soybean)	Safe as used; 2011	Polyurethane-47	24
Oil	Sure as used, 2011	- organomiuno +/	
HDI Polymers	17 are safe as used,	All	29
HDI Folymers	2 insufficient data;	All	
	,		
D'	2016	D 1 1 00	7,8
Bis-	Safe as used; 2014	Polyurethane-28	7,0
Hydroxyethoxypropyl			
Dimethicone			21
Hydroxyethyl	Safe as used; 2016	Polyurethane-9	21
Acrylate/Sodium			
Acryloyldimethyl Taurate			
Copolymer			
Hydroxypropyl	Safe in nail	Polyurethane-51, -52,	11
Methacrylate;	enhancement	-54, -56, -69	
Isopropylidenediphenyl	products when skin		
Bisoxyhydroxypropyl	contact is avoided		
Methacrylate; HEMA			
(Hydroxyethyl			
Methacrylate)			
Isopropanolamine	Safe as used if not	Polyurethane-71	3,16
isopropanoranime	used in products	i oryurculane-/1	
	-		
	containing N-		
	nitrosating		
T / ' A '1/C '''	agents;1987, 2006	D 1 /1 00	9
Isostearic Acid (Sorbitan	Safe as used; 2014	Polyurethane-28	7
Isostearate)			25
Methyl Gluceth-10	Safe as used; 2013	Polyurethane-62	
PEGs; Triethylene Glycol	Triethylene Glycol	Polyurethane-14, -39,	13
	and PEGs ≥4 are	-46, -52, -59, -62	
	safe as used, 2010		
Polyethylene	Safe as used; 2007,	Polyurethane-8	19
	2015		
PPG-3 Butyl Ether; PPG-	Safe when	Polyurethane-67, -68	17,26
30 Butyl Ether	formulated to avoid	•	
	irritation; 2001		
	Insufficient Data		
	Announcement;		
	2016		18
Propylene Glycol; PPGs	Propylene Glycol	Polyurethane-4, -9,	
	and PPGs ≥ 3 are	-14, -36, -67, -68	
	safe when		
	safe when formulated to be		

 Table 2. Previous reports on precursors, monomers, moieties, and related ingredients of polyurethanes in this safety assessment.

Table 3. Precursors, monomers, moieties, and related ingredients of polyurethanes in this safety assessment that are either cosmetic ingredients that have not been reviewed or chemicals that are not cosmetic ingredients.¹

Acetophenone*	N-(3-Aminopropyl)imidazole	Aminpropyl triethoxysilane
bis-Ethylaminoisobutyl-dimethicone	Bisphenol A bis-(2-hydroxypropyl)	Butylene oxide
monomers	ether	
Caprolactone*	Cyclohexanedimethanol*	Decyl Alcohol*
Di-C12-13 Alkyl Tartrate*	3-Diethylamino-1,2-propanediol	Dihydroxypolyoxobutylene
Dilinoleyl Alcohol*	2-Dimethylamino-2-methylpropanol	Dimethylcarbonate-1,6-hexanediol
Dimethyl MEA*	Dimethylolbutanoic acid	Dimethylolpropanoic acid
Dimethylolpropionic acid (DMPA)	Dimethylsulfate	Ethoxylated 4,4'-
		isopropylidenediphenol
2-Ethyl-1-hexanol	Ethylene Carbonate*	Ethylene diamine
Ethylene glycol*	Ethylene oxide	Hydrazine
4-Hydroxybutyl acrylate	3-Hydroxy-2-(hydroxymethyl)-2-	Hydroxypropyl dimethicone*
	methyl-1-propionic acid	
Hydroxybutyl acrylate	Hydroxyethyl acrylate	1-Isobutanol
Isophthalic acid	Isophorone diamine	4,4'-Isopropylidenediphenol*
Lauryl Acrylate*	4,4'-Methylenebis(cyclohexylamine);	N-(2-Aminoethyl)-3-
	saturated methylene	aminoethanesulfonic acid
	diphenyldiisocyanate (SMDI)	
Neopentyl glycol*	Oxymethylene	Poly(1,4)-butanediol
Polyalkylene glycol	Polybutylene glycol	Polycaprolactonetriol
Polyester diol	Polyperfluoroethoxymethoxy	Polytetrahydrofurans (PTHFs)
	Difluorohydroxyethyl Ether*	
Polytetramethylene ether glycol	Polytetramethylene glycol	Propanoic anhydride
Propylene oxide	2-Pyridylethanol	Sodium N-(2-aminoethyl)-3-
		aminoethane sulfonate
Tetradecyloctadeceth	Trimethylamine*	Trimethylolpropane*
Valerolactone*		

valeroractorie.

*Cosmetic ingredient or closely related to a cosmetic ingredient listed in the wINCI that has not been reviewed. These are largely highly reactive molecules and not likely to be a significant component in final formulation and not likely to be released following polymerization and formulated in a cosmetic product.

Table 4. 1	Diisocyanates used in manufacturing polyurethanes in this safety
assessmen	t. ¹

bis(Isocyanatomethyl)benzene	1,3-bis(Isocyanatomethyl)cyclohexane
Diphenylmethane diisocyanate	Cyclic trimer of hexamethylene diisocyanate
Hexamethylenediisocyanate	Isocyanato methylethylbenzene
Isophorone diisocyanate (IPDI)	Methylene bis-(4-cyclohexylisocyanate) (HMDI)
<i>m</i> -Tetramethylene diisocyanate*	meta-Tetramethylenexylenediisocyanate*
Saturated methylene diphenyldiisocyanate (SMDI)	Toluene diisocyanate

* These two ingredients have the same structure.

Property	Value	Reference
Polyu	ırethane-11	
Molecular Weight g/mol	> 1000,000	35
Poly	rethane-14	
Molecular Weight g/mol	> 1000	33
Water Solubility g/L	20,000-35,000 Miscible	64,65
· · ·		
Polyu Viscosity kg/(s m) @ 25°C	0.160	32
Water Solubility	Miscible	32
-	Wilscidle	
Other solubility Propylene glycol	Insoluble	32
Ethanol	Insoluble	32
Dimethicone	Insoluble	32
•	rethane-28	
Molecular Weight g/mol	> 30,000	34
Polyı	irethane-35	
Molecular Weight g/mol	> 1000	36
Disassociation constants (pKa, pKb) @°C pKa	0.5-4.5 est.	36
•		
Polyu Physical Form	r ethane-36^b Liquid	41
Color	Whitish	41
Molecular Weight g/mol	> 50,000	41
Density @ 20°C	~ 1.04	41
Viscosity kg/(s m)	0.02-0.20	41 41
Vapor pressure mmHg @ 20°C	17.25	41
Melting Point °C Boiling Point °C	~ 0 100	41
Water Solubility	Completely miscible	41
·		
Molecular Weight g/mol	> 36,000	34
Molecular Weight g/mol	25,631	43
Polyu Physical Form	rethane-60 ^c Liquid	37
Color	Light yellow	37
Molecular Weight g/mol	> 50,000	37
Density @ 20°C	~1.06	37
Viscosity kg/(s m)	0.05-0.5	37
Vapor pressure mmHg @ 20°C	17.25	37 37
Melting Point °C	~ 0	37
Boiling Point °C Water Solubility	100 Completely miscible	37
	* · · ·	
Polyu Physical Form	rethane-61 ^d Liquid	38
Color	Liquid Light yellow	38
Molecular Weight g/mol	> 50,000	38
Density/Specific Gravity @ 20°C	~ 1.05	38
Viscosity kg/(s m)	0.02-0.5	38
Vapor pressure mmHg @ 20°C	17.25	38
Melting Point °C	~ 0	38
Boiling Point °C	100	38
Water Solubility	Completely miscible	56

Table 5. Chemical and physical properties of polyurethanes.

Table 5.	Chemical	and ph	ysical j	properties	of po	lyurethanes.
----------	----------	--------	----------	------------	-------	--------------

Property	Value	Reference
	Polyurethane-62	
Physical Form	Powder	39
Color	White to off white	39
Molecular Weight g/mol	> 70,000	39
	~ 100,000	40
Density kg/m ³ @ 23°C	1500	39
Water Solubility	Dispersible	39

est.=estimated

^a Polyurethane-21 at 35% in an aqueous dispersion.

^b Polyurethane-36 in an aqueous dispersion with approximately 1.0%-1.5% phenoxyethanol and triethylamine.

^c Polyurethane-60 in an aqueous dispersion with approximately 0.0075%

methylisothiazolinone (MI) and benzisothiazolinone and 1.5% triethylamine. $^{\rm d}$ Polyurethane-61 in an aqueous dispersion with approximately 0.0075% MI and

benzisothiazolinone and 1.5% triethylamine.

Table 6. Methods of manufacture for polyurethanes.

Ingredient	Method of manufacture/monomers	Termination	Notes	Reference
Polyurethane-28	Condensation of an isocyanate component and molecules containing hydroxyl groups (sorbitan isostearate)	Addition of ethyl alcohol		34
Polyurethane-42	Condensation of an isocyanate component and molecules containing hydroxyl groups (di-C12-13 alkyl tartrate and hydrogenated dilinoleyl alcohol)	Addition of ethyl alcohol		34
Polyurethane-62	A proprietary anhydrous reaction		The resulting solid is then ground to the desired particle size.	40
Polyurethane-69	Condensation of an isocyanate component with di teQahQL 13 alkyl tartra isopropylidenediphenyl bisoxyhydroxypropyl methacrylate.	2 -H added to react with terminal isocyanate groups. The reaction is carried on until free isocyanate groups are not detected.		34

Table 7. Polyurethanes that are reported to be supplied in tradename mixtures as dispersions or solutions.

Ingredient	Percentage Solids	Solvent/medium	Reference
Polyurethane-1	30%	Water $\sim 60\%$, ethanol (denatured) $\sim 10\%$	30
Polyurethane-14	20%	Water	33
Polyruethane-21	35%	Water	32
Polyruethane-28	25%	Cyclopentasiloxane	34
Polyurethane-35	40%	Water	36
Polyurethane-36	39.0% - 41.0%	Water, approximately 1.0% - 1.5% (by weight) phenoxyethanol as a preservative and approximately 1.0% - 1.5% triethylamine as a neutralizing agent	41
Polyurethane-39	~ 20%	Water, ~ 1.2% preservative mixture of phenoxyethanol, phenylpropanol, 1,3- propane diol, caprylyl glycol, and α-tocopherol	31
Polyurethane-42	47.50%	Isododecane and ethanol	34
Polyurethane-60	37.0% - 39.0%	Water, approximately 0.0075% MI and benzisothiazolinone as preservatives, and approximately 1.3% (by weight) dimethylethanolamine as a neutralizing agent	37
Polyurethane-61	38.0% - 40.0%	Water, approximately 0.0075% MI and 75 ppm benzisothiazolinone as preservatives, and approximately 1.3% and 1.5% by weight, respectively, dimethylethanolamine as a neutralizing agent	38
Polyurethane-69	66%	Butyl acetate and ethanol	34

Table 8. Frequency of use according to duration and exposure of polyurethanes.
--

Use type	Uses	Maximum Concentration (%)	Uses	Maximum Concentration (%)	Uses	Maximum Concentration (%)	Uses	Maximum Concentration (%)
	Poly	urethane-1	Pol	yurethane-2	Poly	urethane-6	Pol	urethane-7
Total/range	19	0.15-15	13	0.63-9	16	3-6	14	NR
Duration of use ^a								
Leave-on	17	0.5-15	12	0.63-9	13	3-6	14	NR
Rinse-off	2	0.15	1	NR	3	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	10	0.9-4.6	8	NR	NR	NR	NR	NR
Incidental ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-sprays	4;2 ^b	0.5-5	1 ^b ; 3 ^c	NR	8	3-6	NR	NR
Incidental inhalation-powders	NR	NR	3°	0.63; 1.1°	NR	NR	6	NR
Dermal contact	2	2.3	7	0.63-1.1	NR	NR	14	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	9	0.5-5	NR	NR	16	3-6	NR	NR
Hair-coloring	NR	0.15	NR	NR	NR	NR	NR	NR
Nail	NR	15	NR	9	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR

	Polyu	rethane-8	Polyu	rethane-9	Polyu	rethane-10	Polyu	rethane-11
Total/range	1	NR	1	NR	NR	0.098-3	315	0.0015-5.2
Duration of use								
Leave-on	1	NR	1	NR	NR	0.098-3	303	0.0072-5.2
Rinse-off	NR	NR	NR	NR	NR	NR	12	0.016
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	0.0015
Exposure type								
Eye area	NR	NR	NR	NR	NR	0.098	195	0.051-1.5
Incidental ingestion	NR	NR	NR	NR	NR	NR	2	0.058
Incidental Inhalation-sprays	NR	NR	NR	NR	NR	3 ^c	2; 1 ^b ; 2 ^c	0.0072-0.086
Incidental inhalation-powders	NR	NR	NR	NR	NR	NR	2; 2 ^c	3-3.2; 0.024 ^c
Dermal contact	1	NR	1	NR	NR	2	235	0.0015-3.2
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	NR	NR	NR	NR	NR	3	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	0.086
Nail	NR	NR	NR	NR	NR	NR	78	0.06-5.2
Mucous Membrane	NR	NR	NR	NR	NR	NR	14	0.0015-0.058
Baby	NR	NR	NR	NR	NR	NR	NR	NR

Table 8. Frequency of use according to duration and exposure of polyurethanes. ^{45,}	Table 8.	Frequency	of use a	according to	duration a	and exr	osure of	polvurethanes. ⁴	5,46
--	----------	-----------	----------	--------------	------------	---------	----------	-----------------------------	------

		Maximum Concentration		Maximum Concentration		Maximum Concentration		Maximum Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
	Poly	urethane-14	Poly	urethane-15	Polyı	rethane-16	Poly	urethane-18
Total/range	33	0.18-2.8	2	0.01-0.2	1	0.98	11	0.8
Duration of use								
Leave-on	31	0.28	2	0.01-0.2	1	0.98	11	0.8
Rinse-off	2	0.18	NR	NR	NR	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	0.62	NR	NR	NR	NR	NR	NR
Incidental ingestion	NR	NR	NR	0.036	NR	NR	NR	NR
Incidental Inhalation-sprays	10; 15 ^b	0.6-2.4; 0.6-2.8°	NR	NR	NR	NR	3; 7 ^b	NR
Incidental inhalation-powders	NR	NR	1	0.2	NR	NR	NR	NR
Dermal contact	2	0.62-1.5	2	0.01-0.2	1	0.98	1	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	31	0.18-2.8	NR	NR	NR	NR	10	0.8
Hair-coloring	NR	0.63	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	0.036	NR	NR	NR	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR

	Polyu	rethane-24	Polyu	rethane-33	Poly	urethane-34	Polyu	rethane-35
Total/range	NR	0.0018-2	27	0.04-7.5	9	0.36-3.2	18	0.84-7
Duration of use								
Leave-on	NR	0.0018-2	27	0.04-7.5	8	0.36-3.2	18	0.84-7
Rinse-off	NR	NR	NR	NR	1	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	NR	2	0.5-1.8	8	3.2	17	2-7
Incidental ingestion	NR	NR	NR	NR	NR	2.9	NR	NR
Incidental Inhalation-sprays	NR	0.0018	NR	0.04	NR	0.36-0.75; 0.5 ^c	NR	NR
Incidental inhalation-powders	NR	NR	NR	NR	NR	NR	NR	0.84 ^d
Dermal contact	NR	NR	1	0.5-7.5	1	NR	4	0.84-2.9
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	NR	0.0018-2	NR	0.04	NR	0.36-0.75	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	25	0.3-7.5	NR	NR	1	NR
Mucous Membrane	NR	NR	NR	NR	NR	2.9	NR	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR

				15 16
Table 8. Freque	ency of use accordin	g to duration and	exposure of poly	vurethanes. ^{45,46}

		Maximum Concentration		Maximum Concentration		Maximum Concentration		Maximum Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
	Poly	urethane-39	Poly	urethane-40	Polyu	rethane-46		
Total/range	8	NR	9	NR	NR	0.2		
Duration of use								
Leave-on	5	NR	9	NR	NR	NR		
Rinse-off	3	NR	NR	NR	NR	0.2		
Diluted for (bath) use	NR	NR	NR	NR	NR	NR		
Exposure type								
Eye area	NR	NR	3	NR	NR	NR		
Incidental ingestion	NR	NR	NR	NR	NR	NR		
Incidental Inhalation-sprays	3 ^b	NR	2 ^b	NR	NR	NR		
Incidental inhalation-powders	NR	NR	1	NR	NR	NR		
Dermal contact	1	NR	9	NR	NR	NR		
Deodorant (underarm)	NR	NR	NR	NR	NR	NR		
Hair-noncoloring	7	NR	NR	NR	NR	0.2		
Hair-coloring	NR	NR	NR	NR	NR	NR		
Nail	NR	NR	NR	NR	NR	NR		
Mucous Membrane	NR	NR	NR	NR	NR	NR		
Baby	NR	NR	NR	NR	NR	NR		

NR = Not Reported; Totals = Rinse-off + Leave-on + Diluted for Bath Product Uses.

^a Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^b It is possible these products <u>may</u> be sprays, but it is not specified whether the reported uses are sprays. ^c Not specified whether a powder or a spray, so this information is captured for both categories of incidental inhalation.

^d It is possible these products <u>may</u> be powders, but it is not specified whether the reported uses are powders.

Table 9. Polyurethanes that have no reported uses in the VCRP or from an industry survey.^{45,46}

fioli all fildustry s	uivey.	
Polyurethane-4	Polyurethane-5	Polyurethane-12
Polyurethane-13	Polyurethane-17	Polyurethane-19
Polyurethane-20	Polyurethane-21	Polyurethane-23
Polyurethane-25	Polyurethane-26	Polyurethane-27
Polyurethane-28	Polyurethane-29	Polyurethane-32
Polyurethane-36	Polyurethane-41	Polyurethane-42
Polyurethane-43	Polyurethane-44	Polyurethane-45
Polyurethane-47	Polyurethane-48	Polyurethane-49
Polyurethane-50	Polyurethane-51	Polyurethane-52
Polyurethane-53	Polyurethane-54	Polyurethane-55
Polyurethane-56	Polyurethane-57	Polyurethane-58
Polyurethane-59	Polyurethane-60	Polyurethane-61
Polyurethane-62	Polyurethane-63	Polyurethane-64
Polyurethane-65	Polyurethane-66	Polyurethane-67
Polyurethane-68	Polyurethane-69	Polyurethane-70
Polyurethane-71	Polyurethane-72	-

Table 10. Precursors and monomers of the polyurethanes in this safety assessment that may be used in polyurethane resins that are used in adhesives that may come in contact with food in accordance with the FDA. [21CFR175.105]

[2107K173.103]	
1,4-Butanediol	1,4-Butanediol modified with adipic acid
1,4-Cyclohexanedimethanol [part of a polyester resin]	1,6-Hexanediol (CAS Reg. No. 629-11-8) [part of a polyester resin]
2-Hydroxypropyl methacrylate	4,4'-Isopropylidenediphenol
Dehydroacetic acid	Diethanolamine
Diethylene glycol adipic acid copolymer	Diethylene glycol copolymer of adipic acid and phthalic anhydride
Dipropylene glycol copolymer of adipic acid and phthalic anhydride	Ethylene glycol
Ethylenediamine	Ethylenediaminetetra-acetic acid, calcium, ferric, potassium, or
	sodium salts, single or mixed
Fats and oils derived from animal or vegetable sources, and the	Hydroxyacetic acid
hydrogenated, sulfated, or sulfonated forms of such fats and oils	
Isobutyl alcohol (isobutanol)	Isophthalic acid
Isopropanolamine (mono-, di-, tri-)	Monochloracetic acid
Octylphenoxypolyethoxy-polypropoxyethanol (13 moles of	Polybutylene glycol (molecular weight 1,000)
ethylene oxide and propylene oxide)	
Polyester of adipic acid, phthalic acid, and propylene glycol,	Polyethylene glycol (molecular weight 200-6,000)
terminated with butyl alcohol	
Polyethyleneadipate modified with ethanolamine with the molar	Propylene Glycol and <i>p</i> , <i>p</i> '-isopropylidenediphenol diether
ratio of the amine to the adipic acid less than 0.1 to 1	
Tetramethyl decynediol plus 1-30 moles of ethylene oxide	Toluene
Tridecyl alcohol	Triethylene Glycol

Table 11. Genotoxicity studies of polyurethanes.

Ingredient	Concentration/dose	Method	Results	Reference
Polyurethane-1	0 and 64-16,000 μg/plate of 30% Polyurethane-1 in water and ethanol	Ames test, SPT and PIT. Salmonella typhimurium (TA98, TA100, TA1535, and TA1537) and Escherichia coli (WP2 uvrA).	Not mutagenic	30
Polyurethane-21	100%; 35% solids	Ames test using <i>S. typhimurium</i> (strains TA97a, TA98, TA100, TA102, and TA1535)	Not a potential mutagen with and without metabolic activation	85
Polyurethane-28	Not specified	OECD TG 471 (Bacterial Reverse Mutation Test)	Not mutagenic	34
Polyurethane-35	Not specified	OECD TG 471 (Bacterial Reverse Mutation Test)	Not mutagenic	36
Polyurethane-42	Not specified	OECD TG 471 (Bacterial Reverse Mutation Test) using <i>S. typhimurium</i> and <i>E. coli</i>	Not mutagenic	34
Polyurethane-59	0, 312.5, 625, 1250, 2500, and 5000 μg/plate	Ames test, SPT and PIT, using <i>S.</i> <i>typhimurium</i> (TA98, TA100, TA1535, and TA1537) and <i>E. coli</i> (WP2 uvrA)	Not mutagenic	31
Polyurethane-62	Up to 5000 µg/plate (tested without trideceth-6 solvent; not specified if tested in water or other neutral solvent)	Ames test using <i>S. typhimurium</i> (strains TA98, TA100, TA1535, and TA1537) and <i>E. coli</i> (WPluvrA)	No cytotoxicity or precipitation was observed with or without metabolic activation. There were no significant increases in the frequency of revertant colonies.	67

PIT- pre-incubation test SPT- standard plate test

 Table 12. Human sensitization assays of polyurethanes.

Ingredient/test article	Concentration/Dose	Procedure	Results	Reference
Polyurethane-1	30% in a mascara	HRIPT (n=103)	Did not demonstrate a potential for eliciting dermal irritation or sensitization.	73
Polyurethane-1	28.5% in a mascara	HRIPT (n=103)	Did not demonstrate a potential for eliciting dermal irritation or sensitization	72
Polyurethane-14	9.61% solids in 54.9% ethanol. Control was 55% ethanol.	HRIPT (n=104). Semi-occlusion to upper arms of subjects 3 times per week for 3 weeks. Challenge was administered at same concentration. Test material was applied to the patch pad 15-30 min before application to the subjects.	Mild erythema was observed in both treatment and control groups in a few subjects at various evaluation periods during induction. No reaction was observed in any subject during challenge phase. Test material did not yield evidence of delayed contact hypersensitivity response in human subjects.	74
Polyurethane-21	60% in corn oil; 21% solids; 0.2 mL/0.2 g	HRIPT (n=50). Applied under occlusion	No adverse reactions of any kind were observed during the course of the study. Considered a non-primary irritant and a non- primary sensitizer.	75
Polyurethane-21	35% solids; 0.2 mL	HRIPT (n=100). Applied under occlusion	No adverse reactions of any kind were observed during the course of the study. Considered a non-primary irritant and a non- primary sensitizer.	76

Table 13. In vitro ocular assays of polyurethanes

Ingredient	Concentration	Method	Results	Reference
Polyurethane-1	30% in a mascara tested at 0, 5%, 15%, 25%, 35%, and 50%; effective concentrations: 0.015%, 0.045%, 0.075%, 0.105%, and 0.15% Polyurethane-1	NRR using rabbit cornea fibroblasts	NR ₅₀ >50%; equivalent to a Draize score of 0-15 (slight irritant)	77
Polyurethane-1	30% in a mascara	HET-CAM	Mean scores: Hyperhemia - 3.5; hemorrhage-5.0; coagulation-0; overall-8.5. Equivalent to a Draize score of 15.1-30 (moderate irritant)	77
Polyurethane-1	30% in a mascara	REC	Cumulative SMCI-0.71. Slightly cytotoxic; equivalent to a Draize score of 0-15 (slight irritant)	77
Polyurethane-1			Considering the 3 assays above (NRR, HET-CAM, and REC), the estimated Draize classification of the test material might be a slight irritant with an estimated Draize score of 0-15.	77
Polyurethane-1	30% in a mascara tested at 50%; effective concentration-15%	HET-CAM	Mean cumulative score-1.25; predicted to be practically no irritation potential at 100%.	80
Polyurethane-1	30% in a mascara	BCOP	Mean score-1.0; minimally irritating. Estimated Draize score approaching 0 (non- irritant).	79
Polyurethane-1	30% in a mascara; tested at 20%; effective concentration-6%	EpiOcular™	Viability at 20 min-105%; 1 h- 102%; 4 h-92%. $ET_{50}>256$ min. Estimated Draize score approaching 0 (non-irritant).	78
Polyurethane-14	10%, tested at 20%, final concentration 2%	EpiOcular™	$\begin{array}{l} \text{ET}_{50} \text{ was} > 256 \text{ min.} \\ \text{Estimated Draize ocular} \\ \text{irritation score of the test} \\ \text{material at 100\% was 0 and} \\ \text{Polyurethane-14 can be} \\ \text{predicted to be a non-irritant.} \end{array}$	81
Polyurethane-21	100% with 35% solids	HET-CAM	Mean cumulative score-0.50, predicted not to have ocular irritation potential	83
Polyurethane-21	100% with 35% solids	BCOP	Average score of 1.7. Predicted to be a non-irritant and expected to elicit a Draize score approaching 0.	82
Polyurethane-42	100% with 35% solids	HET-CAM	Moderate irritant	34
Polyurethane-42	100% with 35% solids	BCOP	Non-irritant	34 67
Polyurethane-62	Tested without trideceth-6 solvent; not specified if tested in water or other neutral solvent	EpiOcular [™] assay using the reconstructed human cell epithelial (RhCE) model (conducted in accordance with OECD Draft Guideline titled Reconstructed Human Cornea-Like Epithelium (RhCE) Test Method for Identifying Chemicals Not Requiring Classification and Labelling for Eye Irritation or Serious Eye Damage)	Treated cells had 63% survival. Survival >60% is considered negative for ocular irritation. The control had expected result.	07

BCOP = bovine corneal opacity and permeability assay; $ET_{50} =$ The estimated time at which the percent viability would be 50%; HET-CAM = chorioallantoic membrane of the embryonic hen's egg assay; $NR_{50} =$ The amount of test substance that will cause a 50% decrease in neutral red uptake measured by optical density; NRR = Neutral red release assay; REC = Reconstituted human epithelial culture assay; SMCI = Simplified mean cytotoxicity index

REFERENCES

- Nikitakis, J and Lange B (eds). Web-Based Ingredient Dictionary (wINCI). <u>http://webdictionary.personalcarecouncil.org/jsp/Home.jsp</u>. Washington, DC. Last Updated 2017. Date Accessed 8-7-2017.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, and Scott, LN. Safety assessment of alkane diols as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2017. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-79.
- Andersen, FAA. Annual review of cosmetic ingredient safety assessments 2004/2005. International Journal of Toxicology. 2006;25(Suppl 2):1-89.
- 4. Andersen, FA. Annual review of cosmetic ingredient safety assessments: 2005/2006. International Journal of Toxicology. 2008;27(Suppl. 1):77-142.
- 5. Elder, RL. Final report on the safety assessment of butylene glycol, hexylene glycol, ethoxydiglycol, and dipropylene glycol. *Journal of the American College of Toxicology*. 1985;4(5):223-248.
- Fiume, MM, Heldreth, B, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Final report of the Cosmetic Ingredient Review Expert Panel on the safety assessment of dicarboxylic acids, salts, and esters. *International Journal of Toxicology*. 2012;31(Suppl. 1):5S-76S.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, and Becker, LC. Safety assessment of polyoxyalkylene siloxane copolymers, alkyl-polyoxyalkylene siloxane copolymers, and related ingredients as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2014. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-46.
- Andersen, FA. Annual review of cosmetic ingredient safety assessments 2002/2003. International Journal of Toxicology. 2005;24(Suppl. 1):1-102.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Fiume, MM, and Heldreth, B. Safety assessment of sorbitan esters as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2014. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-26.
- Johnson Jr, W, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Safety assessment of 1,2-glycols as used in cosmetics. *International Journal of Toxicology*. 2012;31(Suppl. 2):147S-168S.
- 11. Andersen, FA. Final report of the safety assessment of methacrylate ester monomers used in nail enhancement products. *International Journal of Toxicology*. 2005;24(Suppl. 5):53-100.
- 12. Johnson Jr, W, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Safety assessment of alkyl glyceryl ethers as used in cosmetics. *International Journal of Toxicology*. 2013;32(Suppl. 3):5S-21S.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Amended Safety Assessment of Triethylene Glycol and Polyethylene Glycols (PEGs)-4, -6, -7, -8, -9, -10, -12, -14, -16, -18, -20, -32, -33, -40, -45, -55, -60, -75, -80, -90, -100, -135, -150, -180, -200, -220, -240, -350, -400, -450, -500, -800, -2M, -5M, -7M, -9M, -14M, -20M, -23M, -25M, -45M, -65M, -90M, -115M, -160M and -180M and any PEGs >=4 as used in Cosmetics. Washington, DC, Cosmetic Ingredient Review. 2010. <u>http://www.cir-safety.org/ingredients</u>, pp. 1-49.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, and Fiume, MM. Amended safety assessment of butyl polyoxyalkylene ethers as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2016. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-27.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Andersen, FA, Fiume, MM, and Heldreth, B. Diethanolamine and its salts as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2011. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-28.
- 16. Elder, RL. Final report on the safety assessment of diisopropanolamine, triisopropanolamine, isopropanolamine, and mixed isopropanolamine. Journal of the American College of Toxicology. 1987;6(1):53-76.
- 17. Andersen, FA. Amended final report on the safety assessment of PPG-40 Butyl Ether with an addendum to include PPG-2, -4, -5, -9, -12, -14, -15, -16, -17, -18, -20, -22, -24, -26, -30, -33, -52, and -53 butyl ethers. *International Journal of Toxicology*. 2001;20(Suppl. 4):39-52.
- Fiume, MM, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Safety assessment of Propylene Glycol, Tripropylene Glycol, and PPGs as used in cosmetics. *International Journal of Toxicology*. 2012;31(Suppl 2):245S-260S.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Burnett, C, and Heldreth, B. Safety assessment of polyene group as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2015. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-38.
- 20. Elder, RL. Final report on the safety assessment of Toluene. Journal of the American College of Toxicology. 1987;6(1):77-120.

- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, and Becker, LC. Safety assessment of acryloyldimethyltaurate polymers as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2017. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-21.
- Heldreth, B, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Final report of the Cosmetic Ingredient Review Expert Panel on the safety assessment of Methyl Acetate. *International Journal of Toxicology*. 2012;31(Suppl. 1):112S-136S.
- Fiume, MM, Heldreth, B, Bergfeld, W, Belsito, D, Hill, R, Klaassen, C, Liebler, D, Marks Jr, J, Shank, R, Slaga, T, Snyder, P, and Andersen, F. Safety assessment of alkyl PEG ethers as used in cosmetics. *International Journal of Toxicology*. 2012;31(Suppl. 2):169S-244S.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Andersen, FA, Burnett, C, and Fiume, MM. Final report: plant-derived fatty acid oils as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2011. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-100.
- Bergfeld, WF, Belsito, DV, Klaassen, CD, Liebler, D, Hill, RA, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Johnson Jr, W, and Heldreth, B. Safety assessment of methyl glucose polyethers and esters as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2013. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-39.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Fiume, MM, and Heldreth, B. Amended safety assessment of butyl polyoxyalkylene ethers as used in cosmetics - final amended report. Washington, DC, Cosmetic Ingredient Review. 2017. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-36.
- 27. Bello, D, Herrick, C, Smith, T, Woskie, S, Streicher, R, Cullen, M, Liu, Y, and Redlich, C. Skin exposure to isocyanates: Reason for concern. *Environmental Health Perspectives*. 2006;115(3):328-335.
- Silva, A, Nunes, C, Martins, J, Dinis, T, Lopes, C, Neves, B, and Cruz, T. Respiratory sensitizer hexamethylene diisocyanate ihibits SOD 1 and induces ERK-dependent detoxifying and maturation pathways in dendritic-like cells. *Free Radical Biology and Medicine*. 2014;72:238-246.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, and Becker, LC. Safety Assessment of hexamethylene diisocyanate (HDI) polymers as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2016. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-21.
- 30. BASF. 2008. Information on toxicological data: Luviset P.U.R. (Polyurethane- 1). Unpublished data submitted by Personal Care Products Council.
- 31. BASF. 2014. Information on toxicological data: Luvigel® Star AT 3 (Polyurethane-39). Unpublished data submitted by Personal Care Products Council.
- 32. Phoenix Chemical Inc. 2017. GIOVAREZ® P-0580 (INCI: Polyurethane-21). Unpublished data submitted by Personal Care Products Council.
- 33. National Industrial Chemical Notification and Assessment Scheme (NICNAS). Full Public Report: Polyurethane in DynamX. Sydney, Australia, Australian Government; Department of Health. 8-27-2003. <u>https://www.nicnas.gov.au/__data/assets/pdf_file/0009/9756/PLC371FR.pdf</u>. Date Accessed 10-19-2016. Report No. PLC/371. pp. 1-10.
- 34. Intercos. 2017. CIR review of Polyurethane: Intercos supplementary data (Polyurethane-28, -42 and 69). Unpublished data submitted by Personal Care Products Council.
- 35. Anonymous. 2017. Polyurethane-11. Unpublished data submitted by Personal Care Products Council.
- 36. National Industrial Chemical Notification and Assessment Scheme (NICNAS). Polymer of low concern public report: Polymer in Baycusan C 1004. Sydney, Australia, Australian Government; Department of Health. 2014. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwj1n93fyOfPAhVLkh4KHUjnCNEQFggeM AA&url=https%3A%2F%2Fwww.nicnas.gov.au%2F_data%2Fassets%2Fword_doc%2F0015%2F14334%2FPLC-1228-FR.DOCX&usg=AFQjCNE27i_SktC8BYktMdh8vn9pU-ifjQ&sig2=hbvoZRhg9MxDmoCZuadgrg. Date Accessed 10-19-2016. Report No. PLC/1228. pp. 1-6.
- 37. Anonymous. 2017. Technical information Polyurethane-60. Unpublished data submitted by Personal Care Products Council.
- 38. Anonymous. 2017. Technical information Polyurethane-61. Unpublished data submitted by Personal Care Products Council.
- 39. National Industrial Chemical Notification and Assessment Scheme (NICNAS). Polymer of low concern public report: Z-155 (INCI name: polyurethane-62). Sydney, Australia, Australian Government: Department of Health. 2015. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjqm4CO2ufPAhUGGR4KHRalDyYQFgg eMAA&url=https%3A%2F%2Fwww.nicnas.gov.au%2F_data%2Fassets%2Fword_doc%2F0007%2F18754%2FPLC1260-FR-FINAL.DOCX&usg=AFQjCNG86sWoTX0FE5OogUCn6otTJb6NkQ&sig2=cNMlqvIzfnabM4pa-pcoVQ. Report No. PLC/1260. pp. 1-6.

- 40. Lubrizol Advanced Materials Inc. 2017. Information on Polyurethane-62. Personal communication from Lubrizol Advanced Materials Inc. to Carol Eisenmann, Personal Care Products Council. Unpublished data submitted by Personal Care Products Council.
- 41. Anonymous. 2017. Technical information Polyurethane-36. Unpublished data submitted by Personal Care Products Council.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Burnett, CL, and Boyer, IJ. Amended safety assessment of Methylisothiazolinone as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2014. <u>http://www.cir-safety.org/ingredients</u>. pp. 1-21.
- 43. Anonymous. 2017. Information sheet Polyurethane-59. Unpublished data submitted by Personal Care Products Council.
- European Chemicals Agency (ECHA). Annex XV report: An assessment of whether the use of MDA in articles should be restricted in accordance with Article 69(2) of REACH (4,4'-diaminodiphenylmethane (MDA). Helsinki, Finland, European Chemicals Agency. 2015. <u>https://echa.europa.eu/documents/10162/13641/annex_xv_report_mda_en.pdf</u>. pp. 1-10.
- 45. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients; FDA Database. Washington, DC, FDA. 2017.
- Personal Care Products Council. 12-14-2016. Concentration of Use by FDA Product Category: Polyurethanes. Unpublished data submitted by Personal Care Products Council.
- Bremmer HJ, Prud'homme de Lodder LCH, and van Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. 2006. <u>http://www.rivm.nl/bibliotheek/rapporten/320104001.pdf</u>. Date Accessed 8-24-2011. Report No. RIVM 320104001/2006. pp. 1-77.
- 48. Johnsen MA. The Influence of Particle Size. Spray Technology and Marketing. 2004;14(11):24-27.
- Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, and Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett.* 8-28-2011;205(2):97-104. PM:21669261.
- Rothe H. Special aspects of cosmetic spray safety evaluation. 2011. Unpublished information presented to the 26 September CIR Expert Panel. Washington D.C.
- CIR Science and Support Committee of the Personal Care Products Council (CIR SSC). 11-3-2015. Cosmetic Powder Exposure. Unpublished data submitted by the Personal Care Products Council.
- Aylott RI, Byrne GA, Middleton, J, and Roberts ME. Normal use levels of respirable cosmetic talc: preliminary study. Int J Cosmet Sci. 1979;1(3):177-186. PM:19467066.
- 53. Russell RS, Merz RD, Sherman WT, and Sivertson JN. The determination of respirable particles in talcum powder. *Food Cosmet Toxicol*. 1979;17(2):117-122. PM:478394.
- European Commission. Regulation (EC) No 1223/2009 of the European Parliment and of the Council of 30 November 2009 on cosmetic products. Official Journal of the European Union. 2009;342:59-209. http://ec.europa.eu/health//sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf.
- 55. European Commission. Cosing database. http://ec.europa.eu/growth/tools-databases/cosing/. European Commission. Last Updated 2015.
- Gultekin, G, Atalay-Oral, C, Erkal, S, Sahin, F, Karastova, D, Tantekin-Ersolmaz, S, and Guner, F. Fatty acid-based polyurethane films for wound dressing applications. *Journal of Materials Science.Materials in Medicine*. 2009;20(1):421-431.
- Boateng, JS, Matthews, K, Stevens, H, and Eccleston, G. Wound healing dressings and drug deliver systems: A review. *Journal of Pharmaceutical Sciences*. 2008;97(8):2892-2923.
- 58. Silverira, RC, Bragga, F, Garbin, L, and Galväo, C. The use of polyurethane transparent film in indwelling central venous catheter. *Revista Latino-Americana de Enfermagem*. 2010;18(6):1212-1220.
- Kucinska-Lipka, J, Gubanska, I, Janik, H, and Sienkiewicz, M. Fabrication of polyurethane and polyurethane based composite fibres by the electrospinning techique for soft tissue engineering of cardiovascular system. *Materials Science and Engineering C*. 2015;46(January):166-176.
- 60. Angelova, N and Hunkeler, D. Rationalizing the design of polymeric biomaterials. Trends in Biotechnology. 1999;17(10):409-421.
- Khan, W, Muntimadugu, E, Jaffe, M, and Domb, AJ. Implantable Medical Devices. Chapter: 2. Domb, AJ and Khan, W. In: Focal Controlled Drug Delivery. 1 ed. CRS-Springer Publications US; 2014:33-59.
- 62. Castel, N, Soon-Sutton, T, Deptula, P, Flaherty, A, and Don Parsa, F. Polyurethane-coated breast implants revisited: A 30-year follow-up. Archives of Plastic Surgery. 2015;42(2):186-193.

- 63. Hazard Evaluation System & Information Service (HESIS). Isocyanates: working safetyl [pamphlet]. Richmond, CA: California Department of Public Health, California Department of Industrial Relations; 2014.
- WIL Research Laboratories Inc. 2002. Summary of acute inhalation toxicity study (Polyurethane- 14). Unpublished data submitted by Personal Care Products Council.
- WIL Research Laboratories Inc. 9999. Summary of 14-day inhalation toxicity range-finding study (Polyurethane-14). Unpublished data submitted by Personal Care Products Council [DATE TO BE VERIFIED].
- WIL Research Laboratories Inc. 2003. Summary of 90-day inhalation toxicity range-finding study (Polyurethane-14). Unpublished data submitted by Personal Care Products Council.
- 67. Lubrizol Advanced Materials Inc. 2015. Toxicology Studies: Avalure TM Flex-6 Polymer. Unpublished data submitted by Personal Care Products Council.
- Silva, AH, Locatelli, C, Filippin-Monteiro, F, Martin, P, Liptrott, N, Zanetti-Ramos, B, Benetti, L, Nazan, E, Alburquerque, C, Pasa, A, Owen, A, and Creczynski-Pasa, T. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. *Toxicity Letters*. 2016;246(March):17-27.
- 69. Hill-Top Research Inc. 2017. Summary of 21-day cumulative irritation study in humans (Polyurethane-14). Unpublished data submitted by Personal Care Products Council.
- Product Investigations Inc. 2012. Evaluation of the skin-irritating propensities of GIOVAREZ P-0580 (Polyurethane-21) on scarified skin. Unpublished data submitted by Personal Care Products Council.
- Covance Laboratories Inc. 2001. Summary of dermal sensitization study in guinea pigs maximization test (Polyurethane-14). Unpublished data submitted by Personal Care Products Council.
- 72. Clinical Research Laboratories Inc. 2007. Repeated insult patch test of a mascara containing 28.5% Polyurethane- 1. Unpublished data submitted by Personal Care Products Council.
- 73. Clinical Research Laboratories Inc. 2007. Repeated insult patch test of a mascara containing 30% Polyurethane-1. Unpublished data submitted by Personal Care Products Council.
- 74. Hill-Top Research Inc. 2001. Summary of human repeated insult patch test (Polyurethane-14). Unpublished data submitted by Personal Care Products Council.
- AMA Laboratories Inc. 2004. 50 Human subject repeat insult patch test skin irritation/sensitization evaluation (occlusive patch) GIOVAREZ P-580 (Polyurethane-21). Unpublished data submitted by Personal Care Products Council.
- AMA Laboratories Inc. 2004. 100 Human subject repeat insult patch test skin irritation/sensitization evaluation (occlusive patch) GIOVAREZ P-0580 (Polyurethane-21). Unpublished data submitted by Personal Care Products Council.
- 77. International Research and Development Center. 2007. Assessment of the eye irritating potential of a cosmetic product (mascara containing 30% Polyurethane-I) through alternative methods to the Draize test. Unpublished data submitted by Personal Care Products Council.
- Consumer Product Testing Co. 2007. The MatTek Corporation EpiOcular[™] tissue model in vitro toxicity testing system (mascara containing 30% Polyurethane- 1). Unpublished data submitted by Personal Care Products Council.
- Consumer Product Testing Co. 2007. Bovine corneal opacity and permeability assay (mascara containing 30% Polyurethane- 1). Unpublished data submitted by Personal Care Products Council.
- 80. Consumer Product Testing Co. 2007. The hen's egg test utilizing the chorioallantoic membrane (HET-CAM) (mascara contains 30% Polyurethane-1). Unpublished data submitted by Personal Care Products Council.
- Consumer Product Testing Co. 2008. The MatTek Corporation EpiOcular[™] tissue model in vilro toxicity testing system (test article: pomade containing 10% Polyurethane-14). Unpublished data submitted by Personal Care Products Council.
- Consumer Product Testing Co. 2012. Bovine corneal opacity and permeability assay GIOVAREZ P-0580 (Polyurethane-21). Unpublished data submitted by Personal Care Products Council.
- Consumer Product Testing Co. 2012. The hen's egg test- utilizing the chorioallantoic membrane (HET-CAM) GIOVAREZ P-0580 (Polyurethane-21). Unpublished data submitted by Personal Care Products Council.
- Clinical Research Laboratories Inc. 2007. An in-use safety evaluation to determine the ocular irritation potential of a cosmetic product (mascara 79A contains 30% Polyurethane-I; 79B contains 28.5% Polyurethane-)). Unpublished data submitted by Personal Care Products Council.
- 85. Nelson Laboratories. 2012. The *Salmonella typhimurium* reverse mutation assay (Ames Test), liquids or soluble chemicals final report GIOVAREZ P-0580 (Polyurethane-21). Unpublished data submitted by Personal Care Products Council.